Rajesh Kumar Meher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rajesh Kumar Meher has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Debasmita Dubey
Department of Medical Research, IMS & SUM Hospital, Siksha‘O’Anusandhan (Deemed to be) University, Bhubaneswar, 751003, Odisha, India
4 shared publications - Pradeep Kumar Naik
Centre of Excellence in Natural Products and Therapeutics, Department of Biotechnology and Bioinformatics Sambalpur University Sambalpur Odisha India
2 shared publications - Sadhni Induar
Food Sciences and Technology, Kalinga Institute of Social Sciences, Bhubaneswar, India
2 shared publications - Santosh Kumar Swain
Department of Otorhinolaryngology and Head and Neck Surgery, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India
2 shared publications - Smrutipragnya Samal
Department of Medical Research, IMS & SUM Hospital, Siksha‘O’Anusandhan (Deemed to be) University, Bhubaneswar, 751003, Odisha, India
2 shared publications - Abhilasha Tripathi
Department of Pharmacology King George's Medical University Lucknow India
1 shared publication
Latest Publications
- 11 November 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 22
Apoptotic and Antitumor Effect of Lagerstroemia speciosa (L.) Pers. Leaf Extract in Ovarian Cancer: Role of Intrinsic Pathway and In Silico Prediction of TSPO as a Mitochondrial Target
Introduction: Ovarian cancer remains a leading cause of cancer-related death in women, necessitating a novel therapeutic strategy with minimal side effects. Lagerstroemia speciosa (L.) Pers., a medicinal plant known for its bioactive phytochemicals, has shown potential to induce apoptosis via the intrinsic mitochondrial pathway. This study evaluated the anticancer activities of L. speciosa leaf methanolic extract (L.sp-Met-Ex) in a preclinical ovarian cancer model and to identify molecular targets through in silico analysis. Methods: Cytotoxicity was assessed via SRB assay on OVCAR-3, SK-OV3, A2780, and HEK-293 cells. Apoptosis, cell cycle arrest, and mitochondrial dysfunction were analyzed using flow cytometry, fluorescent staining, and caspase-9 immunofluorescence. In vivo efficacy was performed in a xenograft model. GC-MS profiling was performed, and in silico prediction was used to explore the Translocator Protein (TSPO) as a potential target. Results: L.sp-Met-Ex exhibited dose-dependent cytotoxicity with IC50 values of 25.4 ± 1.5 μg/ml (OVCAR-3), 49.7 ± 1.7 μg/ml (SK-OV3), and 52.3 ± 1.1 μg/ml (A2780), with minimal toxicity toward HEK-293 cells. Treated cells showed apoptosis marked by nuclear fragmentation, mitochondrial depolarization, elevated ROS, and intracellular calcium levels. The extract significantly suppressed tumor growth in vivo. GC-MS identified key phytocompounds that exhibited stable binding to TSPO in simulations. Discussion: L.sp-Met-Ex demonstrates that it induces mitochondrial-mediated apoptosis via ROS generation, calcium dysregulation, and membrane depolarization. TSPO is implicated as a key molecular target, supporting mitochondrial dysfunction as a therapeutic strategy. Conclusion: L.sp-Met-Ex demonstrates anticancer activity via the intrinsic apoptotic pathway and G2/M phase cell-cycle arrest, highlighting TSPO as a therapeutic potential in ovarian cancer.
- 11 November 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 22
Apoptotic and Antitumor Effect of Lagerstroemia speciosa (L.) Pers. Leaf Extract in Ovarian Cancer: Role of Intrinsic Pathway and In Silico Prediction of TSPO as a Mitochondrial Target
Introduction: Ovarian cancer remains a leading cause of cancer-related death in women, necessitating a novel therapeutic strategy with minimal side effects. Lagerstroemia speciosa (L.) Pers., a medicinal plant known for its bioactive phytochemicals, has shown potential to induce apoptosis via the intrinsic mitochondrial pathway. This study evaluated the anticancer activities of L. speciosa leaf methanolic extract (L.sp-Met-Ex) in a preclinical ovarian cancer model and to identify molecular targets through in silico analysis. Methods: Cytotoxicity was assessed via SRB assay on OVCAR-3, SK-OV3, A2780, and HEK-293 cells. Apoptosis, cell cycle arrest, and mitochondrial dysfunction were analyzed using flow cytometry, fluorescent staining, and caspase-9 immunofluorescence. In vivo efficacy was performed in a xenograft model. GC-MS profiling was performed, and in silico prediction was used to explore the Translocator Protein (TSPO) as a potential target. Results: L.sp-Met-Ex exhibited dose-dependent cytotoxicity with IC50 values of 25.4 ± 1.5 μg/ml (OVCAR-3), 49.7 ± 1.7 μg/ml (SK-OV3), and 52.3 ± 1.1 μg/ml (A2780), with minimal toxicity toward HEK-293 cells. Treated cells showed apoptosis marked by nuclear fragmentation, mitochondrial depolarization, elevated ROS, and intracellular calcium levels. The extract significantly suppressed tumor growth in vivo. GC-MS identified key phytocompounds that exhibited stable binding to TSPO in simulations. Discussion: L.sp-Met-Ex demonstrates that it induces mitochondrial-mediated apoptosis via ROS generation, calcium dysregulation, and membrane depolarization. TSPO is implicated as a key molecular target, supporting mitochondrial dysfunction as a therapeutic strategy. Conclusion: L.sp-Met-Ex demonstrates anticancer activity via the intrinsic apoptotic pathway and G2/M phase cell-cycle arrest, highlighting TSPO as a therapeutic potential in ovarian cancer.
- Open Access
- 25 October 2024
- Published by Taylor & Francis in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 52 (1) , 512-528
Exploring the anticancer and antioxidant potential of gold nanoparticles synthesized from Pterocarpus marsupium bark extract against oral squamous cell carcinoma
Oral squamous cell carcinoma (OSCC) is a disease of significant concern with higher mortality rates. Conventional treatment approaches have several drawbacks, leading to the opening of new research avenues in the field of nanoparticle-based cancer therapeutics. The study aimed at the synthesis of gold nanoparticles (Pm-AuNPs) from the aqueous bark extract of Pterocarpus marsupium, followed by its characterization and in vitro anticancer evaluation against OSCC. The synthesized Pm-AuNPs were characterized using UV-visible spectroscopy, particle size analyser, zeta potential, FTIR and SEM techniques. The anticancer potential of the Pm-AuNPs was evaluated against OSCC cell lines (SCC29b, SSC154 and OECM-1) through in vitro assays. The IC50 value was found to be 25 ± 1.2, 45 ± 1.5 and 75 ± 2.1 µg/mL for the three OSCC cell lines, elucidating Pm-AuNPs cytotoxic effects and mechanism of action. Intracellular ROS and SOX detection, mitochondrial transmembrane potential analysis and apoptosis detection were used to confirm the activity of Pm-AuNPs against OSCC. Acute toxicity studies on Wistar rats confirmed the non-toxic nature of the Pm-AuNPs at a higher dose concentration up to 2000 mg/kg body weight. The findings underscore Pm-AuNPs as promising candidates for future anticancer therapeutics, providing insights into their mechanism of action and therapeutic efficacy against OSCC.
- 25 October 2024
- Published by Taylor & Francis in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 52 (1) , 512-528
Open AccessExploring the anticancer and antioxidant potential of gold nanoparticles synthesized from Pterocarpus marsupium bark extract against oral squamous cell carcinoma
Oral squamous cell carcinoma (OSCC) is a disease of significant concern with higher mortality rates. Conventional treatment approaches have several drawbacks, leading to the opening of new research avenues in the field of nanoparticle-based cancer therapeutics. The study aimed at the synthesis of gold nanoparticles (Pm-AuNPs) from the aqueous bark extract of Pterocarpus marsupium, followed by its characterization and in vitro anticancer evaluation against OSCC. The synthesized Pm-AuNPs were characterized using UV-visible spectroscopy, particle size analyser, zeta potential, FTIR and SEM techniques. The anticancer potential of the Pm-AuNPs was evaluated against OSCC cell lines (SCC29b, SSC154 and OECM-1) through in vitro assays. The IC50 value was found to be 25 ± 1.2, 45 ± 1.5 and 75 ± 2.1 µg/mL for the three OSCC cell lines, elucidating Pm-AuNPs cytotoxic effects and mechanism of action. Intracellular ROS and SOX detection, mitochondrial transmembrane potential analysis and apoptosis detection were used to confirm the activity of Pm-AuNPs against OSCC. Acute toxicity studies on Wistar rats confirmed the non-toxic nature of the Pm-AuNPs at a higher dose concentration up to 2000 mg/kg body weight. The findings underscore Pm-AuNPs as promising candidates for future anticancer therapeutics, providing insights into their mechanism of action and therapeutic efficacy against OSCC.
- Open Access
- 25 June 2024
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 17 (2) , 1265-1278
Evaluation of the Antioxidant and Antimicrobial Activity of the Nutritionally Rich Plant, Dioscorea alata L.
Dioscorea alata belongs to Dioscoreaceae or the yam family. Around 600 Dioscorea species are consumed in various regions of the world. Dioscorea alata is well known cultivated tuber consumed by both rural and urban people. In this study, we have investigated the nutrient composition, phytochemicals, and antioxidant and antimicrobial activity of the underground and aerial tubers of Dioscorea alata. The result of the analysis showed that the aerial tuber of D. alata contained a higher amount of moisture (68.51%), ash (4.64%), starch (5.61%), reducing sugar (0.029%), fat (0.33%) and protein (1.39%) than underground tuber of D. alata. At the same time, carbohydrates, free amino acids, vitamin C, sodium, potassium and iron contents were superior in the underground tuber than in the aerial tuber. Further, both underground and aerial tuber was a good source of phenols, flavonoids, tannins and diosgenin. The underground tuber exhibited better DPPH scavenging potential compared to the aerial tuber. Six solvents extract of D. alata showed significant to moderate antibacterial activity toward seven tested clinical stains. Thus, the tuber of D. alata could be used as a better food supplement to meet the calorie requirement and a rich source of relevant antimicrobial agents to treat microbial infections.
- 25 June 2024
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 17 (2) , 1265-1278
Open AccessEvaluation of the Antioxidant and Antimicrobial Activity of the Nutritionally Rich Plant, Dioscorea alata L.
Dioscorea alata belongs to Dioscoreaceae or the yam family. Around 600 Dioscorea species are consumed in various regions of the world. Dioscorea alata is well known cultivated tuber consumed by both rural and urban people. In this study, we have investigated the nutrient composition, phytochemicals, and antioxidant and antimicrobial activity of the underground and aerial tubers of Dioscorea alata. The result of the analysis showed that the aerial tuber of D. alata contained a higher amount of moisture (68.51%), ash (4.64%), starch (5.61%), reducing sugar (0.029%), fat (0.33%) and protein (1.39%) than underground tuber of D. alata. At the same time, carbohydrates, free amino acids, vitamin C, sodium, potassium and iron contents were superior in the underground tuber than in the aerial tuber. Further, both underground and aerial tuber was a good source of phenols, flavonoids, tannins and diosgenin. The underground tuber exhibited better DPPH scavenging potential compared to the aerial tuber. Six solvents extract of D. alata showed significant to moderate antibacterial activity toward seven tested clinical stains. Thus, the tuber of D. alata could be used as a better food supplement to meet the calorie requirement and a rich source of relevant antimicrobial agents to treat microbial infections.
- 29 November 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 43 (2) , 859-873
Phytochemical profiling, in vitro analysis for anti-inflammatory, immunomodulatory activities, structural elucidation and in silico evaluation of potential selective COX-2 and TNF-α inhibitor from Hydrilla verticillata (L.f.) Royle
- 29 November 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 43 (2) , 859-873
Phytochemical profiling, in vitro analysis for anti-inflammatory, immunomodulatory activities, structural elucidation and in silico evaluation of potential selective COX-2 and TNF-α inhibitor from Hydrilla verticillata (L.f.) Royle
- Open Access
- 1 September 2022
- Published by Universitatea Dunarea de Jos din Galati in The Annals of the University Dunarea de Jos of Galati. Fascicle VI - Food Technology
- Vol. 46 (2) , 154-174
Induction of apoptosis on breast adenocarcinoma and suppression of pathogenic bacterial growth by antioxidant rich tuber extract of Dioscorea Bulbifera
Nature derived product drew a lot of interest because of their potential nutritional and therapeutics value. Most natural compounds are now processed and developed as possible antioxidative, antimitotic, antimicrobial, anti-inflammatory, antiangiogenic, and anti-carcinogenic pharmaceutical agents. Indeed, several natural products have been used as lead compounds in the development of most potent physiologically relevant chemicals for therapeutic application. In the current study antioxidant and anticancer potential of tuber extract of Dioscorea bulbifera have been determined as well as its antimicrobial potential against pathogenic bacteria. The IC50 value for the extract was found to be 55µg/ml for MCF-7 and 75µg/ml for MD-AMB-231 human breast cancer adenocarcinoma whereas minimum inhibitory concentration (MIC) value of the methanolic extract against S. aureus was 0.19 mg/ml and minimum bactericidal concentration (MBC) was 1.56 mg/ml. Further to identify compounds responsible for antioxidant, anticancer and antimicrobial activity GCMS analysis of the extract was conducted. Histopathological and haematological assay were carried out on animal model to identify any toxic effect of extract on vital organ system. This study may be used to provide the groundwork for the creation of novel nature-derived drugs whose biological activity can be determined by further purification, characterization, and validation of the active phytochemicals and their mechanism of action.
- 1 September 2022
- Published by Universitatea Dunarea de Jos din Galati in The Annals of the University Dunarea de Jos of Galati. Fascicle VI - Food Technology
- Vol. 46 (2) , 154-174
Open AccessInduction of apoptosis on breast adenocarcinoma and suppression of pathogenic bacterial growth by antioxidant rich tuber extract of Dioscorea Bulbifera
Nature derived product drew a lot of interest because of their potential nutritional and therapeutics value. Most natural compounds are now processed and developed as possible antioxidative, antimitotic, antimicrobial, anti-inflammatory, antiangiogenic, and anti-carcinogenic pharmaceutical agents. Indeed, several natural products have been used as lead compounds in the development of most potent physiologically relevant chemicals for therapeutic application. In the current study antioxidant and anticancer potential of tuber extract of Dioscorea bulbifera have been determined as well as its antimicrobial potential against pathogenic bacteria. The IC50 value for the extract was found to be 55µg/ml for MCF-7 and 75µg/ml for MD-AMB-231 human breast cancer adenocarcinoma whereas minimum inhibitory concentration (MIC) value of the methanolic extract against S. aureus was 0.19 mg/ml and minimum bactericidal concentration (MBC) was 1.56 mg/ml. Further to identify compounds responsible for antioxidant, anticancer and antimicrobial activity GCMS analysis of the extract was conducted. Histopathological and haematological assay were carried out on animal model to identify any toxic effect of extract on vital organ system. This study may be used to provide the groundwork for the creation of novel nature-derived drugs whose biological activity can be determined by further purification, characterization, and validation of the active phytochemicals and their mechanism of action.
- Open Access
- 1 June 2020
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 12, 4519-4530
Mitochondrial Stress–Mediated Targeting of Quiescent Cancer Stem Cells in Oral Squamous Cell Carcinoma
Introduction: Despite improved therapeutics in oral squamous cell carcinoma (OSCC), tumor cells that are either quiescent and/or endowed with stem cell–like attributes usually survive treatment and recreate tumor load at relapse. Through this study, we aimed strategically to eliminate these stem cell–like cancer cells using a combination drug approach. Methods: Primary cultures from 15 well–moderately differentiated OSCC were established, and the existence of cancer cells with stem cell–like characteristics using five cancer stem cell (CSC) specific markers — CD44, CD133, CD147, C166, SOX2 and spheroid assay was ascertained. Next, we assessed quiescence in CSCs under normal and growth factor–deprived conditions using Ki67. Among several gene signatures regulating quiescent cellular state, we evaluated the effect of inhibiting Dyrk1b in combination with topoisomerase II and histone deacetylase inhibitors in targeting quiescent CSCs. Multiple drug-effect analysis was carried out with CompuSyn software to determine combination-index values. Results: We observed that CD44+CD133+ showed the highest level of SOX2 expression. CSCs showed varying degrees of quiescence, and inhibition of Dyrk1b decreased quiescence and sensitized CSCs to apoptosis. In the drug-combination study, Dyrk1b inhibitor was combined with topoisomerase II and histone deacetylase inhibitors to target quiescent CSCs. In combination, a synergistic effect was seen even at a 16-fold lower dose than IC50. Furthermore, combined treatment decreased glutathione levels and increased ROS and mitochondrial stress, leading to increased DNA damage and cytochrome c in CSCs. Conclusion: We report marker-based identification of CSC subpopulations and synergy of Dyrk1b inhibitor with topoisomerase II and HDAC inhibitors in primary OSCC. The results provide a new therapeutic strategy to minimize quiescence and target oral CSCs simultaneously.
- 1 June 2020
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 12, 4519-4530
Open AccessMitochondrial Stress–Mediated Targeting of Quiescent Cancer Stem Cells in Oral Squamous Cell Carcinoma
Introduction: Despite improved therapeutics in oral squamous cell carcinoma (OSCC), tumor cells that are either quiescent and/or endowed with stem cell–like attributes usually survive treatment and recreate tumor load at relapse. Through this study, we aimed strategically to eliminate these stem cell–like cancer cells using a combination drug approach. Methods: Primary cultures from 15 well–moderately differentiated OSCC were established, and the existence of cancer cells with stem cell–like characteristics using five cancer stem cell (CSC) specific markers — CD44, CD133, CD147, C166, SOX2 and spheroid assay was ascertained. Next, we assessed quiescence in CSCs under normal and growth factor–deprived conditions using Ki67. Among several gene signatures regulating quiescent cellular state, we evaluated the effect of inhibiting Dyrk1b in combination with topoisomerase II and histone deacetylase inhibitors in targeting quiescent CSCs. Multiple drug-effect analysis was carried out with CompuSyn software to determine combination-index values. Results: We observed that CD44+CD133+ showed the highest level of SOX2 expression. CSCs showed varying degrees of quiescence, and inhibition of Dyrk1b decreased quiescence and sensitized CSCs to apoptosis. In the drug-combination study, Dyrk1b inhibitor was combined with topoisomerase II and histone deacetylase inhibitors to target quiescent CSCs. In combination, a synergistic effect was seen even at a 16-fold lower dose than IC50. Furthermore, combined treatment decreased glutathione levels and increased ROS and mitochondrial stress, leading to increased DNA damage and cytochrome c in CSCs. Conclusion: We report marker-based identification of CSC subpopulations and synergy of Dyrk1b inhibitor with topoisomerase II and HDAC inhibitors in primary OSCC. The results provide a new therapeutic strategy to minimize quiescence and target oral CSCs simultaneously.